


Pre-Eclampsia Therapeutics Drugs and Companies Pipeline Market H1 2016

WiseGuyReports.com adds "Pre-Eclampsia - Pipeline Review, H1 2016" new report to its research database.

PUNE, INDIA, May 4, 2016 /EINPresswire.com/ -- The report "Pre-Eclampsia - Pipeline Review, H1 2016" provides comprehensive information on the therapeutics under development for Pre-Eclampsia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pre-Eclampsia and features dormant and discontinued projects.

Complete Report Details Available at https://www.wiseguyreports.com/reports/pre-eclampsia-pipeline-review-h1-2016.

This report features investigational drugs from across globe covering over 20 therapy areas and



The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Inquire more about this report at https://www.wiseguyreports.com/enquiry/pre-eclampsia-pipeline-review-h1-2016.

Pre-Eclampsia - Companies Involved in Therapeutics Development: A1M Pharma AB Alnylam Pharmaceuticals, Inc. Glenveigh Medical, LLC Pluristem Therapeutics Inc.



rEVO Biologics, Inc. RTI International VG Life Sciences, Inc.

Featured News & Press Releases

Jan 14, 2016: St. John Hospital Enrolling Patients in Phase 3 Trial for Early Onset Preeclampsia Jan 06, 2016: New Peer Reviewed Article Describes Mechanism of Action of PLX-PAD in

Ameliorating Preeclampsia and Indicates Their Superiority Over Other Cells

Dec 31, 2015: U.S. Food & Drug Administration Grants Orphan Drug Designation to Pluristem's PLX-PAD Cells for Treatment of Severe Preeclampsia

Sep 24, 2015: New clinical trial at SLU treats preeclampsia in second-trimester pregnancies Sep 12, 2014: Alnylam Broadens Pipeline with ALN-AGT, a Subcutaneously Administered RNAi Therapeutic Targeting Angiotensinogen for the Treatment of Hypertensive Disorders of Pregnancy, Including Preeclampsia

Sep 10, 2014: Pluristem to Deliver Scientific Presentations at 3rd International Placenta Stem Cell Society Meeting

Jul 23, 2014: rEVO Biologics Announces Enrollment of First Patient in Phase 3 Trial of ATryn to Treat Early Onset Preeclampsia (PRESERVE-1)

Jul 08, 2014: Orphan Drug Designation Granted in Europe for A1M Pharma's Treatment for Preeclampsia

Mar 31, 2014: rEVO Biologics Initiates PRESERVE-1 Phase 3 Clinical Trial for ATryn in Early-Onset Preeclampsia

Feb 25, 2014: rEVO Biologics Announces the Submission of an IND for ATryn in Preeclampsia

Get a sample copy at https://www.wiseguyreports.com/sample-request/pre-eclampsia-pipeline- review-h1-2016.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pre-Eclampsia
- The report reviews pipeline therapeutics for Pre-Eclampsia by companies and universities/research institutes based on information derived from company and industryspecific sources
- The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Pre-Eclampsia therapeutics and enlists all their major and minor projects
- The report assesses Pre-Eclampsia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Pre-Eclampsia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Pre-Eclampsia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Pre-Eclampsia pipeline

depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Order a Purchase Report Copy @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=443174.

Norah Trent WiseGuy Research Consultants Pvt. Ltd. 16468459349 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.